Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study

Clinical Genitourinary Cancer

Volumn 7, Issue 2, 2009, Pages

  Joly, Florence ^a,i   Houédé, Nadine ^b   Noal, Sabine ^a   Chevreau, Christine ^c   Priou, Frank ^d   Chinet Charrot, Paule ^e   Rolland, Frédéric ^f   Fléchon, Aude ^g   Henry Amar, Michel ^a   Culine, Stéphane ^h  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b INSTITUT BERGONIÉ   (France)

^c Institut Claudius Rigaud   (France)

^d French Federation of Cancer Centers (FNCLCC)   (France)

^e CENTRE HENRI BECQUEREL   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g CENTRE LÉON BÉRARD   (France)

^h CENTRE VAL D AURELLE   (France)

ⁱ Centre François   (France)

Author keywords

Metastasis; Palliative therapy; Relapse; Urothelial cancer

Indexed keywords

ANALGESIC AGENT; CISPLATIN; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; RANITIDINE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CREATININE BLOOD LEVEL; DEPRESSION; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FLUSHING; FRANCE; HUMAN; INFECTION; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PERFORMANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROTHELIAL CARCINOMA; VOMITING;

EID: 70449345853     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.018     Document Type: Article

References (30)

1. Culine S. The present and future of combination chemotherapy in bladder cancer. Semin Oncol 2002; 29:32-39
2. Von Der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608
3. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17:3173-3181
4. Bajorin DF. Paclitaxel in the treatment of advanced urothelial cancer. Oncology (Williston Park) 2000; 14:43-52, 57.
5. Raghavan D. Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer 2003; 97:2050-2055
6. Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361
7. Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACTtaxane). Cancer 2003; 98:822-831
8. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570-579
9. Conroy T, Mercier M, Bonneterre J, et al. French version of FACT-G: validation and comparison with other cancer-specific instruments. Eur J Cancer 2004; 40:2243-2252
10. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151
11. Rothman KJ, Boice JD, Jr. Epidemiologic Analysis With a Programmable Calculator. Boston, MA: Epidemiology Resources; 1982.
12. Wartelle M, Kramar A, Jan P, et al. "PIGAS": An interactive statistical database management system, in Hammond R, McCarthy JL (eds): Proceedings of the Second International Workshop on Statistical Database Management. Springfield, VA, National Technical Information Service, Departement of Commerce. 1983.
13. De Santis M, Bachner M. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol 2007; 17:363-368
14. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94:1395-1401
15. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005; 174:14-20.
16. Scher H, Bahnson R, Cohen S, et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 1998; 12:225-271
17. Marchetti P, Urien S, Cappellini GA, et al. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002; 44(suppl):S3-13.
18. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2003; 2:141-146
19. Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-940
20. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15:3441-3445
21. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997; 15:589-593
22. Raghavan D, Huben R. Management of bladder cancer. Curr Probl Cancer 1995; 19:1-64.
23. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185-1191
24. Sternberg CN. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Curr Opin Urol 2001; 11:523-529
25. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92:2993-2998
26. Albers P, Siener R, Hartlein M, et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 2002; 25:47-52.
27. Schrier BP, Peters M, Barentsz JO, et al. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006; 49:698-703.
28. Fields-Jones S, Koletsky A, Wilding G, et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999; 10:1307-1310
29. Joly F, Vardy J, Pintilie M, et al. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007; 18:1935-1942
30. Koopmans PP. Clinical endpoints in trials of drugs for cancer: time for a rethink? BMJ 2002; 324:1389-1391